Inici › Mieloma múltiple › Minnesota › Rochester
Assaigs clínics de Mieloma múltiple a Rochester, MN
24 estudis de Mieloma múltiple busquen participants en centres de Rochester i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Reclutant
- Mayo Clinic in Rochester, Rochester
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
ReclutantEstudi observacional
- Mayo Clinic in Rochester, Rochester
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Mayo Clinic, Rochester
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Mayo Clinic Rochester, Rochester
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
ReclutantFase 3
- Mayo Clinic, Rochester
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutantFase 4
- Mayo Clinic Rochester, Rochester
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ReclutantFase 2/3
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic in Rochester, Rochester
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 2
- Mayo Clinic in Rochester, Minnesota, Rochester
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic Rochester, Rochester
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
ReclutantFase 2
- Mayo Clinic in Rochester, Rochester
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutantFase 3
- Mayo Clinic in Rochester, Rochester
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic - Transplant Center - Rochester, Rochester
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutantFase 1/2
- Research Site, Rochester
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- Mayo Clinic - Minnesota, Rochester
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic - Rochester /ID# 251164, Rochester
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
ReclutantFase 1
- Mayo Clinic, Rochester
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
ReclutantFase 1/2
- Mayo Clinic in Rochester, Rochester
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
ReclutantFase 3
- Mayo Clinic in Rochester, Rochester
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
ReclutantFase 1
- Mayo Clinic in Rochester, Rochester
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Reclutant
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Mayo Clinic, Rochester
Family Study of Lymphoproliferative Disorders
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Mayo Clinic, Rochester
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
- Seattle, WA22 estudis
Altres estudis a Rochester
- Càncer de mama42 estudis
- Càncer de pulmó de cèl·lules no petites37 estudis
- Càncer metastàtic31 estudis
- Càncer (tots els tipus)30 estudis
- Càncer colorrectal29 estudis
- Càncer d'ovari29 estudis
- Càncer de pròstata22 estudis
- Insuficiència cardíaca22 estudis
- Càncer de pàncrees22 estudis
- Càncer de pulmó20 estudis
- Càncer d'endometri20 estudis
- Leucèmia limfàtica crònica19 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.